Logo image of NDVA.CA

INDIVA LTD (NDVA.CA) Stock Fundamental Analysis

TSX-V:NDVA - TSX Venture Exchange - CA45580J1012 - Common Stock - Currency: CAD

0.03  -0.01 (-14.29%)

Fundamental Rating

2

Taking everything into account, NDVA scores 2 out of 10 in our fundamental rating. NDVA was compared to 34 industry peers in the Pharmaceuticals industry. NDVA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NDVA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NDVA had negative earnings in the past year.
NDVA had a negative operating cash flow in the past year.
NDVA had negative earnings in each of the past 5 years.
NDVA had negative operating cash flow in 4 of the past 5 years.
NDVA.CA Yearly Net Income VS EBIT VS OCF VS FCFNDVA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M -20M

1.2 Ratios

NDVA has a Return On Assets (-11.73%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -11.73%
ROE N/A
ROIC N/A
ROA(3y)-25.75%
ROA(5y)-29.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NDVA.CA Yearly ROA, ROE, ROICNDVA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

The Gross Margin of NDVA (29.21%) is comparable to the rest of the industry.
NDVA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NDVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y45.31%
NDVA.CA Yearly Profit, Operating, Gross MarginsNDVA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

0

2. Health

2.1 Basic Checks

NDVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NDVA has more shares outstanding than it did 1 year ago.
NDVA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NDVA has about the same debt to assets ratio.
NDVA.CA Yearly Shares OutstandingNDVA.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
NDVA.CA Yearly Total Debt VS Total AssetsNDVA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -1.80, we must say that NDVA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.80, NDVA is in line with its industry, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.8
ROIC/WACCN/A
WACC6.06%
NDVA.CA Yearly LT Debt VS Equity VS FCFNDVA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

NDVA has a Current Ratio of 0.70. This is a bad value and indicates that NDVA is not financially healthy enough and could expect problems in meeting its short term obligations.
NDVA has a worse Current ratio (0.70) than 74.29% of its industry peers.
NDVA has a Quick Ratio of 0.70. This is a bad value and indicates that NDVA is not financially healthy enough and could expect problems in meeting its short term obligations.
NDVA has a Quick ratio of 0.45. This is in the lower half of the industry: NDVA underperforms 68.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.45
NDVA.CA Yearly Current Assets VS Current LiabilitesNDVA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.50% over the past year.
NDVA shows a small growth in Revenue. In the last year, the Revenue has grown by 7.30%.
NDVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 264.60% yearly.
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
Revenue 1Y (TTM)7.3%
Revenue growth 3Y36.88%
Revenue growth 5Y264.6%
Sales Q2Q%-0.89%

3.2 Future

Based on estimates for the next years, NDVA will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
NDVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.68% yearly.
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.86%
Revenue Next 2Y11.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NDVA.CA Yearly Revenue VS EstimatesNDVA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
NDVA.CA Yearly EPS VS EstimatesNDVA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 -0.05 -0.1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NDVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDVA.CA Price Earnings VS Forward Price EarningsNDVA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDVA.CA Per share dataNDVA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

A more expensive valuation may be justified as NDVA's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NDVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDIVA LTD

TSX-V:NDVA (6/12/2024, 7:00:00 PM)

0.03

-0.01 (-14.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-23 2024-05-23
Earnings (Next)08-27 2024-08-27
Inst Owners0.1%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.86M
Analysts80
Price Target0.15 (400%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.19
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.21%
FCFM N/A
ROA(3y)-25.75%
ROA(5y)-29.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y45.31%
F-Score5
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 722.14%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.45
Altman-Z -1.8
F-Score5
WACC6.06%
ROIC/WACCN/A
Cap/Depr(3y)221.04%
Cap/Depr(5y)519.22%
Cap/Sales(3y)2.84%
Cap/Sales(5y)253.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.3%
Revenue growth 3Y36.88%
Revenue growth 5Y264.6%
Sales Q2Q%-0.89%
Revenue Next Year15.86%
Revenue Next 2Y11.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year332.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.9%
OCF growth 3YN/A
OCF growth 5YN/A